A5012095302- Pancreatic and Hepatic Oncology Research
- Epigenetics and DNA Methylation
- Cancer Research and Treatments
- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Neuroendocrine Tumor Research Advances
- Renal cell carcinoma treatment
- Inflammatory Biomarkers in Disease Prognosis
- Mobile Health and mHealth Applications
- Adenosine and Purinergic Signaling
- Pancreatitis Pathology and Treatment
- Social Media in Health Education
- Cannabis and Cannabinoid Research
- BRCA gene mutations in cancer
- Colorectal Cancer Treatments and Studies
- Remote Sensing and LiDAR Applications
- Acute Kidney Injury Research
- Digital Mental Health Interventions
- Impact of Light on Environment and Health
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Research Studies
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Recreation, Leisure, Wilderness Management
- Economic and Financial Impacts of Cancer
Princess Margaret Cancer Centre
2019-2024
University of Toronto
2024
Seattle University
2024
University Health Network
2020-2023
Weatherford College
2022
KU Leuven
2020
Abstract Purpose: To determine the impact of basal-like and classical subtypes in advanced pancreatic ductal adenocarcinoma (PDAC) to explore GATA6 expression as a surrogate biomarker. Experimental Design: Within COMPASS trial, patients proceeding chemotherapy for PDAC undergo tumor biopsy RNA-sequencing (RNA-seq). Overall response rate (ORR) overall survival (OS) were stratified by according received. Correlation with using gene profiling, situ hybridization (ISH) was explored. Results:...
Modified FOLFIRINOX (mFFX) and gemcitabine/nab-paclitaxel (GnP) remain standard first-line options for patients with advanced pancreatic ductal adenocarcinoma (PDAC). Human equilibrative nucleoside transporter 1 (hENT1) was hypothesized to be a biomarker of gemcitabine in the adjuvant setting, conflicting results. In this study, we explore hENT1 mRNA expression as predictive PDAC.COMPASS prospective observational trial PDAC. A biopsy required prior initiating chemotherapy, determined by...
Abstract Patient-derived xenograft (PDX) and their xenograft-derived organoid (XDO) models that recapitulate the genotypic phenotypic landscape of patient cancers could help to advance research lead improved clinical management. PDX were established from 276 pancreato-duodenal biliary cancer resections. Initial, passage 0 (P0) engraftment rates 59% (118/199) for pancreatic, 86% (25/29) duodenal, 35% (17/48) ductal tumors. Pancreatic adenocarcinoma (PDAC), had a P0 rate 62% (105/169). KRAS...
Renal ischemia-reperfusion (IR) injury leading to cell death is a major cause of acute kidney injury, contributing morbidity and mortality. Autophagy counteracts by removing damaged macromolecules organelles, making it an interesting anchor point for treatment strategies. However, autophagy also suggested enhance when the ischemic burden too strong. To investigate whether role depends on severity stress, we analyzed dynamics apoptosis in IR rat model with mild (45 min) or severe (60 renal...
Wearable digital health technologies and mobile apps (personal [DHTs]) hold great promise for transforming research care. However, engagement in personal DHT is poor.
Abstract Objectives To evaluate gadoxetic acid-enhanced liver MRI (EOB-MRI) versus contrast-enhanced computed tomography (CECT) for preoperative detection of metastasis (LM) and reduction open-close laparotomies pancreatic ductal adenocarcinoma (PDAC). Methods Sixty-six patients with PDAC had undergone EOB-MRI CECT. LM by CECT their impact on surgical planning, were compared clinical radiology reports retrospective analysis imaging two blinded independent readers. Histopathology or follow-up...
741 Background: Whole genome sequencing (WGS) can reveal patterns of substitution base signatures and structural variation consistent with tumours deficient in homologous recombination repair. We evaluated the published HRDetect score a novel HRD hallmark (HS) patients receiving combination chemotherapy (cCT) on COMPASS trial for advanced PDAC. Methods: The HRD-HS incorporates 10 genomic characteristics HRD-PDAC ≥ 4 defining HRD. an ≥0.7 were applied to WGS data overall survival (OS)...
4024 Background: Median overall survival (mOS) for advanced pancreatic ductal adenocarcinoma (PDAC) is ≤1 year. However, there are patients (pts) who live >2 years on chemotherapy and those rapidly progress prior to a first scan, underscoring biological heterogeneity in PDAC subgroups. Understanding these differences important clinical trial design provides prognostic information pts. Methods: Clinical molecular data (WGS RNAseq) from pts with diagnosis of locally or metastatic enrolled...
<sec> <title>BACKGROUND</title> Wearable digital health technologies and mobile apps (personal [DHTs]) hold great promise for transforming research care. However, engagement in personal DHT is poor. </sec> <title>OBJECTIVE</title> The objective of this paper to describe how participant techniques different study designs affect adherence, retention, overall involving DHTs. <title>METHODS</title> Quantitative qualitative analysis factors are reported across 6 unique studies that adopted...
Background: Pancreatic ductal adenocarcinoma (PDAC) presents significant challenges in diagnosis, staging, and appropriate treatment. Furthermore, patients with PDAC often experience complex symptomatology psychosocial implications that require multi-disciplinary inter-professional supportive care management from health professionals. Despite these hurdles, the implementation of clinic approaches showed promise enhancing clinical outcomes. To assess effectiveness such an approach, we...
4150 Background: Modified FOLFIRINOX (mFFX) and gemcitabine + nab-paclitaxel (GnP) are current 1 st line options in advanced PDAC. GATA6 expression, a transcription factor identifies the classical phenotype is associated with superior overall survival (OS), low predicts basal-like phenotype, poorer prognosis. We have previously established high concordance between expression by RNAseq situ hybridization (ISH). Recent studies suggest difference primary tumor anatomical locations, it unknown...
<div>AbstractPurpose:<p>Modified FOLFIRINOX (mFFX) and gemcitabine/nab-paclitaxel (GnP) remain standard first-line options for patients with advanced pancreatic ductal adenocarcinoma (PDAC). Human equilibrative nucleoside transporter 1 (hENT1) was hypothesized to be a biomarker of gemcitabine in the adjuvant setting, conflicting results. In this study, we explore hENT1 mRNA expression as predictive PDAC.</p>Experimental Design:<p>COMPASS prospective observational...
4011 Background: Human equilibrative nucleoside transporter 1 (hENT1) belongs to a family of transporters critical entry gemcitabine into cells. The prognostic and predictive characteristics this biomarker in pancreatic ductal adenocarcinoma (PDAC) have primarily been evaluated by immunohistochemistry, with conflicting results. We explored the impact hENT1 gene expression Comprehensive Molecular Characterization Advanced Ductal Pancreas Adenocarcinoma for Better Treatment Selection (COMPASS)...
469 Background: The Gustave Roussy Immune Score (GRIm-S) considers a composite of neutrophil to lymphocyte ratio (> 6 = 1), albumin (< 35 1) and LDH ULN has been established as prognostic score may in aid the selection patients for phase 1 trials immune checkpoint inhibitors. Methods: We explored impact GRIm-S (high > enrolled on COMPASS trial correlated with genomic clinical characteristics. Patients this had biopsies whole RNA sequencing prior standard chemotherapy regimens...
4630 Background: The HRDetect score uses whole genome sequencing (WGS) to incorporate patterns of substitution base signatures and structural variation identify tumours deficient in homologous recombination repair (HRD). HRD-tumours, with a higher mutational burden, may be more immunogenic. Methods: We applied 182 resected pancreatic cancers (PDA) 233 advanced PDA enrolled on the COMPASS trial; both cohorts underwent WGS after tumour enrichment. Patients were classified as high( hi ) or low(...
4142 Background: KRAS mutations (m) (KRASm) are present in over 90% of pancreatic adenocarcinomas (PDAC) with a predominance G12 substitutions. wildtype (WT) PDAC relies on alternate oncogenic drivers, and the prognostic impact these remains unknown. We evaluated alterations WT explored specific KRASm status survival. Methods: WGS RNAseq were performed 570 patients (pts) ascertained through our translational research program from 2012-2021, which 443 included for overall survival (OS)...
Abstract Background: Predictors of response to DNA damaging agents may expand the population patients who could benefit from platinum and/or PARP inhibition in pancreatic cancer (PDAC). The HRDetect score derived whole genome sequencing (WGS) incorporates patterns substitution base signatures and structural variation is associated with tumours deficient homologous recombination repair (HRD). Methods: prospective COMPASS trial (NCT 02750657) enrolls advanced PDAC prior systemic treatment for...
4149 Background: Systemic inflammatory scores have been developed as tools to aid clinicians in prognostication and patient (pt) selection for clinical trials. We compared the accuracy of five prognostic predict overall survival (OS) pts with advanced pancreatic adenocarcinoma (PDAC). Methods: Pts PDAC enrolled on COMPASS trial (NCT02750657) from 2015 2020 were included. All had biopsies whole genome RNA sequencing prior standard first-line chemotherapy setting. Prognostic risk was...
430 Background: Familial pancreatic cancer (FPC) is broadly defined as kindreds with at least a pair of first-degree relatives ductal adenocarcinoma (PDA). The role DNA damage response agents, including platinum has not been well studied in this patient population. Methods: In retrospective analysis, treatment details and clinical outcomes were analyzed pts FPC advanced, unresectable or recurrent disease enrolled the Ontario Pancreatic Cancer Study database. primary outcome, overall survival...
396 Background: BRCA1/2 and PALB2 are genes critical to the faithful repair of double strand breaks through homologous recombination (HRR) pathway. Alterations in these serve as predictive biomarkers both platinum PARP inhibitors. Ataxia-telangiectasia mutated ( ATM) is also indirectly involved HRR; however, its role a biomarker DNA damage response agents debated. Herein we evaluated genomic characteristics clinical outcomes patients with ATM alterations on Comprehensive Molecular...